WHO Issues First Global Doxy-PEP Recommendation, With Mandatory Testing Built In

*Originally surfaced May 28, 2026.*

On May 28, 2026, the World Health Organization issued its first global recommendation for doxycycline post-exposure prophylaxis, commonly called doxy-PEP, as a tool for preventing bacterial sexually transmitted infections in selected populations. The recommendation focuses on men who have sex with men and transgender women who have had a recent bacterial STI or who are otherwise at substantial risk, and aligns the global guidance closely with the framework U.S. clinicians have been operating under since the CDC's 2024 guidance.

The regimen WHO endorses is a single 200 mg dose of doxycycline taken within 72 hours of condomless sex, with a maximum of one dose every 24 hours. That part is not new. What is genuinely new, and what is most relevant to anyone thinking about lab testing, is that WHO builds three things into the protocol itself rather than treating them as nice-to-haves:

* Quarterly syphilis serology, meaning RPR or VDRL plus a treponemal antibody test, every three months for as long as a person is on doxy-PEP * A quarterly bacterial STI panel covering chlamydia and gonorrhea at the sites of exposure, which for most users means urine plus pharyngeal and rectal swabs * Local resistance monitoring, particularly for tetracycline resistance in gonorrhea, as a condition of program continuation

The testing components are not framed as optional. WHO treats them as part of what makes doxy-PEP a coherent public-health intervention rather than an unsupervised personal habit.

## Why the testing component matters

The most important real-world finding about doxy-PEP in the last year has been that protection against gonorrhea is fragile. A May 7, 2026 Lancet Infectious Diseases study from Southern California found that gonorrhea protection in doxy-PEP users dropped sharply as tetracycline-resistant strains spread, while protection against chlamydia and syphilis held. We covered that finding in our earlier hot take.

The practical implication is that someone using doxy-PEP cannot safely assume they are protected against gonorrhea. They can still acquire it, they can still pass it on, and the only way to know is to test on a regular cadence.

WHO's quarterly cadence reflects that reality. It is consistent with the CDC's existing guidance that STI screening should happen every three to six months for people on doxy-PEP. Quarterly is the tighter, more cautious end of that range.

## What the new guidance does not change

Doxy-PEP is not HIV prevention. Anyone using or considering doxy-PEP and at risk of HIV exposure should still consider HIV PrEP, which is a separate and more effective intervention for HIV specifically. Doxy-PEP does not protect against viral STIs such as HSV or HPV. WHO's guidance leaves all of that intact.

The recommendation also does not address cisgender women, cisgender heterosexual men, or transgender men. Evidence in those populations remains thin. Some local jurisdictions have moved ahead of the evidence in those groups, but WHO has not.

## What this means for ordering tests

For someone already in a doxy-PEP program with a clinician, this is a reminder that the testing cadence is part of the protocol, not extra. For someone considering doxy-PEP, this is a useful baseline expectation for what their care plan should include.

LevelPanel offers self-pay options for the bacterial STI screening components WHO references. Background pages: the Basic STD Panel and the Expanded STD Panel summarize what each panel covers. A standalone syphilis test is available for people whose only outstanding need is the quarterly syphilis serology. A chlamydia and gonorrhea test covers the two most common bacterial STIs.

A self-pay test does not replace clinical care, and it does not address the resistance-monitoring component of WHO's guidance, which depends on lab-based isolate testing performed under public-health oversight. For background on related symptoms and risk, see our pages on STD symptoms and chlamydia symptoms.

This article is editorial commentary and is not medical advice. Decisions about doxy-PEP, testing frequency, and STI prevention should be made with a qualified clinician.